GRAIL, Inc. $GRAL Shares Bought by Strs Ohio

Strs Ohio raised its stake in GRAIL, Inc. (NASDAQ:GRAL) by 95.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 16,600 shares of the company’s stock after purchasing an additional 8,100 shares during the quarter. Strs Ohio’s holdings in GRAIL were worth $858,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of GRAL. N.E.W. Advisory Services LLC acquired a new position in GRAIL in the 4th quarter valued at $26,000. Comerica Bank grew its stake in shares of GRAIL by 59.2% during the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after purchasing an additional 173 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in GRAIL during the fourth quarter worth about $28,000. Elyxium Wealth LLC acquired a new stake in shares of GRAIL during the 4th quarter valued at approximately $31,000. Finally, Intesa Sanpaolo S.p.A. purchased a new stake in shares of GRAIL during the 4th quarter worth approximately $44,000.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. TD Cowen lifted their price objective on GRAIL from $65.00 to $69.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. Mizuho began coverage on GRAIL in a report on Friday, April 10th. They issued a “neutral” rating and a $58.00 target price on the stock. Wolfe Research started coverage on GRAIL in a research report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Guggenheim cut their price target on GRAIL from $130.00 to $75.00 and set a “buy” rating for the company in a research note on Monday, March 30th. Finally, Robert W. Baird set a $70.00 price objective on shares of GRAIL in a research note on Wednesday, May 6th. Four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, GRAIL currently has a consensus rating of “Hold” and a consensus target price of $67.00.

Key Headlines Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: GRAIL shares are drawing buying interest despite the lawsuit headlines, suggesting some traders may be focusing on the stock’s volatility and potential for a rebound. Article Title
• Neutral Sentiment: Several firms, including Rosen, Faruqi & Faruqi, Pomerantz, Levi & Korsinsky, and others, are reminding investors of the August 4 lead-plaintiff deadline in the pending class action. Article Title
• Neutral Sentiment: The class action itself appears to be focused on alleged investor harm tied to the February 20 trial disclosure and the period from May 13, 2025 through February 19, 2026. Article Title
• Negative Sentiment: The repeated legal notices reinforce a significant litigation overhang and keep attention on the earlier $2.2 billion market-cap wipeout, which can weigh on sentiment toward GRAL. Article Title

Insider Transactions at GRAIL

In other GRAIL news, insider Andrew John Partridge sold 1,491 shares of GRAIL stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $61.08, for a total value of $91,070.28. Following the completion of the sale, the insider owned 163,738 shares in the company, valued at $10,001,117.04. The trade was a 0.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.83% of the company’s stock.

GRAIL Stock Performance

GRAL stock opened at $70.14 on Thursday. The company has a 50 day moving average price of $63.37 and a two-hundred day moving average price of $70.11. The stock has a market capitalization of $3.01 billion, a P/E ratio of -6.76 and a beta of 3.22. GRAIL, Inc. has a one year low of $29.95 and a one year high of $118.84.

GRAIL (NASDAQ:GRAL) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.76) by $0.47. The business had revenue of $40.78 million for the quarter, compared to analysts’ expectations of $39.16 million. GRAIL had a negative return on equity of 16.42% and a negative net margin of 253.22%. Research analysts forecast that GRAIL, Inc. will post -10.91 earnings per share for the current fiscal year.

GRAIL Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.